#EULAR2023 #POS1128 Promising new therapy on the block for #lupus nephritis. A single arm Phase 2a study showed Zetomipozomib, selective immunoproteosome-i + MMF showed about 2/3 pts met =>50% reduction in uPCR at WK24. No safety signal including low IgG or infection @RheumNow https://t.co/0A8cCW5GVV

#EULAR2023 #OP0226 DORIS remission in #SLE is a goal but may be slight tricky to achieve. Multicentre cohort study showed attainment of LLDAS protected against subsequent Flare and Damage @RheumNow https://t.co/MIypIDW6aE

We know HCQ adherence is poor in both RA and SLE >50% in this BC 🇨🇦 cohort All despite being such an important medicine What’s super interesting are the trajectories of adherence - and we’d like to understand more about what motivates each group OP0222 #EULAR2023 @RheumNow https://t.co/rbx1l9T36C

Antimalarial adherence in RA and SLE showed 4 patterns of adherence over time, with 53% drop off in 1 year, with higher adherence with age, SLE and socioeconomic class, Hoque MR, Abst#0222 #EULAR2023 @RheumNow https://t.co/Bld5kWVQxE

Fatigue in SLE remains a challenge! Online digital tool - LEAF - Lupus Expert System for Assessment of Fatigue - assement of fatigue PROMs in 1250pts - 80% reported fatigue, 93% found tool helpful @rheumnow #EULAR2023 Need more tools to assess and manage fatigue! abst#OP0230

#EULAR2023 POS1190-HPR Besides genetic influence, what do patients with #SLE think re: cause of the disease? A survey in N=290 in Sweden showed stress, hormones & infection as the next top 3 causes. Those reported the first two had different education & perceived health @RheumNow https://t.co/GhyCyp7EWU

Watch: Baricitinib in Lupus Nephritis Dr. Peter Nash reports on abstract OP0053 presented at EULAR 2023 in Milan, Italy. https://t.co/U9sIkCs7dX https://t.co/MgmVHo7wZo

• https://bit.ly/3qkSnKs

Lots of early pipeline data in lupus at #EULAR2023 mainly in the supplement! AFIMETORAN dual TLR7/8 ANTAGONIST in lupus mice! Maybe steroid sparing! Abst#AB0132 @RheumNow

#lupus Phase 1 data #EULAR2023 humanised, afucosyl IgG1 antibody against CXCR5 – receptor on B cells and bonafide T follicular helper(Tfh) and circulating T follicular helper-like(cTfh) cells – Potent, tolerated and caused depletion of cells in SLE and RA. Abst#AB0511 @rheumnow

bone complications #SLE – imp to maintain vitamin D levels! Osteonecrosis of the femoral head (ONFH) and Avascular osteonecrosis (AVN) – total 86 pts – 60 had both ONFN and AVN. ONFN often b/l more morbidity, raynauds and low vit D compared to AVN Abst#AB0566#EULAR2023 @rheumnow

Overview of treatment strategies in #Lupus #EULAR2023 #Rheumtwitter https://t.co/zL1nEDajsb

#EULAR2023 #POS0112 Consistent with clinical response, Post-hoc analyses of Phase 2 RCT of Deucravacitinib (Tyk2-i) showed this therapy suppressed both IFN and B cell pathways - a broader mode of action in reducing #SLE pathophysiology. Look forward to Phase 3 results @RheumNow https://t.co/UoZ2xS3IzC